View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 28, 2022

Kiora gets approval to begin Phase Ib retinitis pigmentosa trial

The open-label, first-in-human, single ascending dose trial will analyse KIO-301 in individuals with retinitis pigmentosa.

Kiora Pharmaceuticals has obtained approval to commence the Phase Ib ABACUS clinical trial of the investigational therapy, KIO-301, to restore lost vision in retinitis pigmentosa patients.

A visible light-sensitive small molecule, KIO-301 works as a reversible ‘photoswitch’, specifically made for restoring the ability of the eyes to perceive and interpret light in patients who are visually impaired. 

It enters retinal ganglion cells that downstream degenerated rods and cones and ‘switches’ them into light-sensing cells, which alerts the brain on the presence or absence of visible light.

The open-label, first-in-human, single ascending dose trial will analyse KIO-301 in individuals with retinitis pigmentosa. 

This single-site trial will be carried out at The Royal Adelaide Hospital (RAH) in Adelaide, South Australia.

Kiora Pharmaceuticals chief development officer Eric Daniels said: “This is a pivotal development for Kiora as we pursue the goal of restoring functional vision in patients living with retinitis pigmentosa. 

“We anticipate beginning enrolment of this study in the third quarter of this year and reporting interim data from this trial by the end of this year.”

An inherited genetic eye disease, retinitis pigmentosa causes severe loss of functional vision because of the retinal photoreceptor (rods and cones) degeneration.

In March this year, the US Food and Drug Administration granted Orphan Drug Designation for KIO-301 to treat retinitis pigmentosa. 

To encourage firms in developing therapies for rare conditions, the orphan drug status provides advantages such as facilitated development discussions with the regulatory agency, tax credits for trials, user fee waiver for a marketing application and longer market exclusivity of up to seven years.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena